Form 4: Anteris Director John Seaberg Receives Equity Grant

Anteris Technologies Global Corp. Director John D. Seaberg was granted 139,386 Restricted Stock Units, vesting over time.

Summary

• John D. Seaberg, a Director of Anteris Technologies Global Corp. (AVR), acquired 139,386 Restricted Stock Units (RSUs) on December 3, 2025.
• The first grant consists of 83,333 RSUs, which will vest in three approximately equal annual installments on December 16, 2025, December 16, 2026, and December 16, 2027, contingent on continued service.
• The second grant consists of 56,053 RSUs, which will vest on the earlier of December 3, 2026 (the first anniversary of the grant date) or the date of the next annual stockholders meeting, also subject to continued service.
• Each RSU represents a right to receive one share of Anteris Technologies Global Corp. common stock.
• Following these transactions, John D. Seaberg beneficially owns 83,333 RSUs from the first grant and 56,053 RSUs from the second grant directly.

Sentiment

Score: 6

Explanation: The filing reports a routine equity grant to a director, which is a positive for aligning interests but not a significant event that would drastically alter the company's financial outlook or operations. It's a standard disclosure.

Positives

• The grant of Restricted Stock Units aligns the director's long-term interests with those of the company's shareholders, promoting sustained performance and retention.
• Equity compensation is a standard practice for attracting and retaining qualified board members in publicly traded companies.

Risks

• The vesting of the Restricted Stock Units is subject to the reporting person's continued service through each vesting date, meaning the director must remain with the company to realize the full benefit.
• The ultimate value of the RSUs is dependent on the future market price of Anteris Technologies Global Corp. common stock, introducing market risk.

Future Outlook

The vesting schedules for the Restricted Stock Units extend through December 2027, indicating an expectation of continued service from Director John D. Seaberg and a long-term alignment of his interests with the company's performance.

Industry Context

The grant of Restricted Stock Units to a director is a common and widely accepted practice in the biotechnology and medical device industries, as well as across publicly traded companies generally. This form of compensation is designed to incentivize long-term commitment and align the interests of board members with those of shareholders.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to directors is a standard compensation practice across publicly traded companies globally, including those in the medical technology sector.
• This approach aligns with corporate governance benchmarks that emphasize linking director compensation to long-term shareholder value creation and retention.
• Many peer companies in the medical device and biotechnology space, such as Medtronic, Edwards Lifesciences, and Boston Scientific, routinely utilize equity-based compensation, including RSUs, for their non-employee directors.
• While the specific size of this grant would typically be benchmarked against peer group companies of similar market capitalization and industry, this filing does not provide that comparative data. However, the mechanism of compensation is consistent with industry norms.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with shareholder value creation, potentially leading to more shareholder-friendly decisions and long-term focus.
• Employees: No direct impact on general employees is indicated by this filing, but it reflects the company's compensation practices for its leadership.

Next Steps

• The Restricted Stock Units will vest according to their respective schedules on December 16, 2025, December 3, 2026 (or earlier), December 16, 2026, and December 16, 2027, subject to continued service.

Key Dates

Keywords

Anteris Technologies Global Corp, AVR, Restricted Stock Units, RSU, Equity Grant, Director Compensation, Insider Transaction, Form 4, Corporate Governance